CN114222753A - 一种预防和/或治疗神经母细胞瘤的多肽药物及其用途 - Google Patents

一种预防和/或治疗神经母细胞瘤的多肽药物及其用途 Download PDF

Info

Publication number
CN114222753A
CN114222753A CN202080057168.XA CN202080057168A CN114222753A CN 114222753 A CN114222753 A CN 114222753A CN 202080057168 A CN202080057168 A CN 202080057168A CN 114222753 A CN114222753 A CN 114222753A
Authority
CN
China
Prior art keywords
leu
gly
neuroblastoma
asp
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080057168.XA
Other languages
English (en)
Other versions
CN114222753B (zh
Inventor
杨宝峰
杨新春
赵金龙
袁野
刘宇
王准
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhuhai Teng Pai Pharmaceutical Co ltd
Original Assignee
Zhuhai Teng Pai Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhuhai Teng Pai Pharmaceutical Co ltd filed Critical Zhuhai Teng Pai Pharmaceutical Co ltd
Publication of CN114222753A publication Critical patent/CN114222753A/zh
Application granted granted Critical
Publication of CN114222753B publication Critical patent/CN114222753B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

一种多肽、含有多肽的组合物及其在制备用于预防和/或治疗神经母细胞瘤的药物中的用途。

Description

PCT国内申请,说明书已公开。

Claims (9)

  1. PCT国内申请,权利要求书已公开。
CN202080057168.XA 2020-02-13 2020-02-17 一种预防和/或治疗神经母细胞瘤的多肽药物及其用途 Active CN114222753B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010089778X 2020-02-13
CN202010089778.XA CN113244370A (zh) 2020-02-13 2020-02-13 一种预防和/或治疗神经母细胞瘤的多肽药物及其用途
PCT/CN2020/075599 WO2021159546A1 (zh) 2020-02-13 2020-02-17 一种预防和/或治疗神经母细胞瘤的多肽药物及其用途

Publications (2)

Publication Number Publication Date
CN114222753A true CN114222753A (zh) 2022-03-22
CN114222753B CN114222753B (zh) 2022-10-04

Family

ID=77219776

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010089778.XA Pending CN113244370A (zh) 2020-02-13 2020-02-13 一种预防和/或治疗神经母细胞瘤的多肽药物及其用途
CN202080057168.XA Active CN114222753B (zh) 2020-02-13 2020-02-17 一种预防和/或治疗神经母细胞瘤的多肽药物及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010089778.XA Pending CN113244370A (zh) 2020-02-13 2020-02-13 一种预防和/或治疗神经母细胞瘤的多肽药物及其用途

Country Status (3)

Country Link
US (2) US20230181696A1 (zh)
CN (2) CN113244370A (zh)
WO (1) WO2021159546A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104530199A (zh) * 2014-11-18 2015-04-22 哈尔滨医科大学 一种抗肿瘤多肽及其制备方法和应用
WO2017016430A1 (zh) * 2015-07-27 2017-02-02 上海吉贝医药科技有限公司 一种肿瘤抑制肽
CN107778362A (zh) * 2017-11-22 2018-03-09 哈尔滨医科大学 一种用于抑制口腔鳞状细胞癌迁移和侵袭能力的多肽及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037871A1 (en) * 1999-11-22 2001-05-31 Childrens Hospital Los Angeles Research Institute Method of treating neuroblastoma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104530199A (zh) * 2014-11-18 2015-04-22 哈尔滨医科大学 一种抗肿瘤多肽及其制备方法和应用
WO2017016430A1 (zh) * 2015-07-27 2017-02-02 上海吉贝医药科技有限公司 一种肿瘤抑制肽
CN107778362A (zh) * 2017-11-22 2018-03-09 哈尔滨医科大学 一种用于抑制口腔鳞状细胞癌迁移和侵袭能力的多肽及其用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EMMANUEL JOUANNEAU ET AL: "Lack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft modelLack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft model", 《JOURNAL OF NEURO-ONCOLOGY》 *
MINORU KUROIWA ET AL: "Continuous Versus Intermittent Administration of Human Endostatin in Xenografted Human Neuroblastoma", 《JOURNAL OF PEDIATRIC SURGERY》 *
MINORU KUROIWA ET AL: "Effects of recombinant human endostatin on a human neuroblastoma xenograft", 《INTERNATIONAL JOURANL OF MOLECULAR MEDICINE》 *
XIAONA DONG ET AL: "A LC-MS/MS method to monitor the concentration of HYD-PEP06, a RGD-modified Endostar mimetic peptide in rat blood", 《JOURNAL OF CHROMATOGRAPHY B》 *

Also Published As

Publication number Publication date
US20240207367A1 (en) 2024-06-27
CN113244370A (zh) 2021-08-13
CN114222753B (zh) 2022-10-04
WO2021159546A1 (zh) 2021-08-19
US20230181696A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
JP2005508856A (ja) 血管形成を阻害する方法
JP2015051970A (ja) 化学療法を受けているがん患者向けのアジュバントを製造するための組成物
CN111803493A (zh) 马来酸替加色罗在制备抗肿瘤药物中的应用
EP3320901B1 (en) Dimethylaminomicheliolide for use in the treatment of pulmonary fibrosis
KR102011105B1 (ko) 고시폴 및 펜포르민을 유효성분으로 포함하는 췌장암 예방 및 치료용 약학적 조성물
WO2020224609A1 (zh) 激酶抑制剂的用途
CN114222753B (zh) 一种预防和/或治疗神经母细胞瘤的多肽药物及其用途
CN114222580B (zh) 一种预防和/或治疗卵巢癌的多肽药物及其用途
CN114949000B (zh) 麝香提取物及其增强car-t细胞疗效的应用
CN115177620A (zh) 西奥罗尼或其药学上可接受的盐在制备预防或治疗滤泡淋巴瘤的药物中的应用
CN111803484B (zh) 奥替溴铵在制备抗肿瘤药物中的应用
KR20210076863A (ko) 니클로사마이드를 포함하는 섬유증의 예방 및 치료용 조성물
CN108853114B (zh) 硝呋莫司在制备治疗癌症衍生的脑转移瘤的药物中的应用
CN111803482B (zh) 鹿茸单体在制备抑制乳腺肿瘤骨转移的药物中的应用及药物
CN111574590B (zh) 一种具有抗肿瘤功能的多肽及其应用
CN109674788B (zh) 羧胺三唑与ido1抑制剂组合在抗肿瘤中的用途
CN110179804B (zh) Reversan在制备预防和治疗心脏病药物中应用
RU2212240C1 (ru) Способ лечения туберкулеза
RU2211035C1 (ru) Противотуберкулезный препарат
JP2024502336A (ja) がんを治療するための医薬組成物、その製造方法及び使用
CN115227690A (zh) 土木香内酯在双表达型b细胞淋巴瘤中的应用
CN118304412A (zh) 一种特异性阻断acvr1c与grem1结合的多肽及其应用
CN118766907A (zh) 羧胺三唑在制备治疗肿瘤骨转移的药物中的用途
CN117122606A (zh) 淫羊藿次苷i在治疗或预防微卫星稳定型实体瘤中的应用及包含其的药盒
CN117653645A (zh) 仙茅苷在防治椎间盘退变中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: Yang Xinchun

Inventor after: Zhao Jinlong

Inventor after: Yang Baofeng

Inventor after: Yuan Ye

Inventor after: Liu Yu

Inventor after: Wang Zhun

Inventor before: Yang Baofeng

Inventor before: Yang Xinchun

Inventor before: Zhao Jinlong

Inventor before: Yuan Ye

Inventor before: Liu Yu

Inventor before: Wang Zhun

CB03 Change of inventor or designer information
GR01 Patent grant
GR01 Patent grant